GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ZELTIQ Aesthetics Inc (NAS:ZLTQ) » Definitions » Altman Z-Score

ZELTIQ Aesthetics (ZELTIQ Aesthetics) Altman Z-Score : 19.42 (As of May. 04, 2024)


View and export this data going back to 2011. Start your Free Trial

What is ZELTIQ Aesthetics Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

ZELTIQ Aesthetics has a Altman Z-Score of 19.42, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for ZELTIQ Aesthetics's Altman Z-Score or its related term are showing as below:


ZELTIQ Aesthetics Altman Z-Score Historical Data

The historical data trend for ZELTIQ Aesthetics's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZELTIQ Aesthetics Altman Z-Score Chart

ZELTIQ Aesthetics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Altman Z-Score
Get a 7-Day Free Trial 4.27 15.51 19.74 13.56 15.51

ZELTIQ Aesthetics Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.56 12.35 9.97 14.20 15.51

Competitive Comparison of ZELTIQ Aesthetics's Altman Z-Score

For the Medical Devices subindustry, ZELTIQ Aesthetics's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZELTIQ Aesthetics's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ZELTIQ Aesthetics's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where ZELTIQ Aesthetics's Altman Z-Score falls into.



ZELTIQ Aesthetics Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

ZELTIQ Aesthetics's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.4316+1.4*-0.4154+3.3*0.0692+0.6*29.3337+1.0*1.6525
=19.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2016:
Total Assets was $214.3 Mil.
Total Current Assets was $165.3 Mil.
Total Current Liabilities was $72.8 Mil.
Retained Earnings was $-89.0 Mil.
Pre-Tax Income was 15.308 + 12.161 + -2.137 + -10.554 = $14.8 Mil.
Interest Expense was 0 + 0 + -0.02 + -0.036 = $-0.1 Mil.
Revenue was 105.11 + 95.157 + 89.465 + 64.469 = $354.2 Mil.
Market Cap (Today) was $2,247.5 Mil.
Total Liabilities was $76.6 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(165.264 - 72.759)/214.345
=0.4316

X2=Retained Earnings/Total Assets
=-89.032/214.345
=-0.4154

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(14.778 - -0.056)/214.345
=0.0692

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=2247.490/76.618
=29.3337

X5=Revenue/Total Assets
=354.201/214.345
=1.6525

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

ZELTIQ Aesthetics has a Altman Z-Score of 19.42 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


ZELTIQ Aesthetics  (NAS:ZLTQ) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


ZELTIQ Aesthetics Altman Z-Score Related Terms

Thank you for viewing the detailed overview of ZELTIQ Aesthetics's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ZELTIQ Aesthetics (ZELTIQ Aesthetics) Business Description

Traded in Other Exchanges
N/A
Address
ZELTIQ Aesthetics Inc was incorporated in Delaware in March 2005 as Juniper Medical, Inc. In July 2007, it changed its name to ZELTIQ Aesthetics, Inc. ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled cooling technology platform. Its first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.
Executives
Todd Erik Zavodnick officer: President, International C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Bradley Hauser officer: SVP, Research and Development C/O ZELTIQ AESTHETICS, INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Danika R Harrison officer: SVP of Global Marketing C/O ZELTIQ AESTHETICS, INC. 4410 ROSEWOOD DRIVE PLEASANTON CA 94588
Mark J Foley director, officer: President and CEO ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Taylor C. Harris officer: SVP & Chief Financial Officer 6035 STONERIDGE DRIVE, PLEASANTON CA 94588
Kevin C Oboyle director 5964 LA PLACE COURT, CARLSBAD CA 92008
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
D Keith Grossman director
Andrew N Schiff director, 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Keith J Sullivan officer: CCO, President, North America C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Patrick F. Williams officer: SVP & CFO C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Leonard C Debenedictis officer: Chief Technical Officer C/O RELIANT TECHNOLOGIES, INC., 464 ELLIS STREET, MOUNTAIN VIEW CA 94043
Bryan E Roberts director C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Jean George director CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Aisling Capital Iii Lp 10 percent owner 888 Seventh Avenue, 30th Fl, New York NY 10106

ZELTIQ Aesthetics (ZELTIQ Aesthetics) Headlines

No Headlines